Sun Yat-sen University: Stomach Neoplasms trials

The registry lists 28 Stomach Neoplasms studies with Sun Yat-sen University as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 2 13Phase 3 10No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric CancerRecruitingNCT06451211Phase 2
• A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR VariantNot yet recruitingNCT05997459Phase 2
• Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Phase 3
• Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable FactorRecruitingNCT03399253Phase 2/3
• Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric CancerActive, not recruitingNCT04250948Phase 2
• Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric CancerStatus unknownNCT04086888
• Prediction of the Efficacy of ctDNA in Immunotherapy for Advanced Gastric CancerStatus unknownNCT04053725
• PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.CompletedNCT03755440Phase 2
• Maintenance Treatment With S-1 in Gastric Cancer PatientsStatus unknownNCT03701373Phase 2
• Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant ChemotherapyStatus unknownNCT03654534Phase 3
• Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.Status unknownNCT03144843Phase 2
• IV Ascorbic Acid in Advanced Gastric CancerStatus unknownNCT03015675Phase 3
• ctDNA for Prediction of Relapse in Gastric CancerStatus unknownNCT02887612
• Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B CarriersStatus unknownNCT02777801Phase 2
• Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)CompletedNCT02745509Not applicable
• Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric CancerCompletedNCT02229058Phase 2
• Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric CancerStatus unknownNCT02229045Phase 2
• Study of S-1 Plus LV for Advanced Gastric CancerCompletedNCT02090153Phase 2
• Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerCompletedNCT02004769Phase 2
• Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric CarcinomaStatus unknownNCT02002416
• Functional Jejunal Interposition Improve Nutritional Status After Total GastrectomyStatus unknownNCT01996059Phase 3
• Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After ChemotherapyCompletedNCT01953419Phase 2
• Lauren Classifications and HER2 Status in Gastric Cancer PatientsStatus unknownNCT01927146
• S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma PatientsCompletedNCT01824459Phase 3
• Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric CancerCompletedNCT01815853Phase 3
• Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric CancerStatus unknownNCT01795027Phase 3
• Trial of S-1 Plus Cisplatin in Gastric CancerStatus unknownNCT01198392Phase 3
• Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI TumorStatus unknownNCT01048463Phase 3